miR Scientific, LLC

miR Scientific, LLC is a leading healthcare company dedicated to revolutionizing cancer management on a global scale through innovative diagnostic solutions. Committed to early and precise detection, characterization, and monitoring of disease, miR Scientific has developed the groundbreaking miR Disease Management Platform®, a proprietary, non-invasive system initially focused on urological cancers.

The cornerstone of this platform is the miR Sentinel® Prostate Cancer Test, a liquid biopsy urine test that offers unparalleled accuracy in detecting, classifying, and monitoring prostate cancer. This is achieved through the interrogation of small non-coding RNAs extracted from urinary exosomes. With a focus on prostate, bladder, and other urothelial cancers, miR Scientific is actively developing interoperable products and services to redefine the standards of care in urologic oncology. The primary address of miR Scientific is 250 Greenwich St, New York, US, with an additional location at 1 Discovery Drive, Room 230, Rensselaer, NY 12144, US.

miR Scientific is poised to significantly impact patient outcomes through its dedication to innovation and precision medicine. The company's commitment extends beyond diagnostics, aiming to provide comprehensive solutions that address the urgent global need for improved cancer care. We invite the management team at miR Scientific, LLC to create a customized and exclusive company showcase and product listing on our platform, further amplifying their reach and impact.